ARCHIVES

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Senate Raises Funding For Cervical, Ovarian, Prostate Cancer

September 18, 1992

NCI Cancer Education Program To Open To Innovative Ideas

April 2, 1993

BCDDP Follow Up To Cost $1.6 Million annually For Five Years Okayed; Limited To 59,000 Women

November 3, 1978

Kessler Promises Cancer Patient Liaison In FDA; Considers Joint Drugs, Biologics Oncology Review

August 14, 1992

NCAB Task Force Urges New Study Section For Clinical Cancer Research, Sees “Crisis”

May 7, 1993

NRC Group Splits Over chemical Dose Testing For Carcinogenicity

March 12, 1993